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Abstract 18 
 19 
During the replication of parainfluenza virus type 5 (PIV5) copyback defective virus 20 
genomes (DVGs) are erroneously produced and are packaged into “infectious” virus 21 
particles.  Copyback DVGs are primary inducers of innate intracellular responses, 22 
including the interferon (IFN) response. Whilst DVGs can interfere with the 23 
replication of non-defective (ND) virus genomes and activate the IFN-induction 24 
cascade before ND PIV5 can block the production of IFN, we demonstrate that the 25 
converse is also true, i.e. high levels of ND virus can block the ability of DVGs to 26 
activate the IFN-induction cascade. By following the replication and amplification of 27 
DVGs in A549 cells that are deficient in a variety of innate intracellular antiviral 28 
responses, we show that DVGs induce an uncharacterised IFN-independent innate 29 
response(s) that limits their replication. High throughput sequencing was used to 30 
characterise the molecular structure of copyback DVGs. Whilst there appears to be 31 
no sequence-specific break or rejoining points for the generation of copyback DVGs, 32 
our finds suggest that there are region, size and/or structural preferences selected 33 
for during for their amplification. 34 
 35 
Importance 36 
Copyback defective virus genomes (DVGs) are powerful inducers of innate 37 
immune responses both in vitro and in vivo. They impact the outcome of natural 38 
infections, may help drive virus‐host co‐evolution, and promote virus persistence. 39 
Due to their potent interfering and immunostimulatory properties, DVGs may also be 40 
used therapeutically as antivirals and vaccine adjuvants. However, little is known of 41 
the host cell restrictions which limit their amplification.  We show here that the 42 
generation of copyback DVGs readily occurs during parainfluenza virus type 5 (PIV5) 43 
replication but that their subsequent amplification is restricted by the induction of 44 
innate intracellular responses. Molecular characterisation of PIV5 copyback DVGs 45 
suggests that whilst there are no genome sequence specific breaks or rejoin points 46 
for the generation of copyback DVGs, genome region, size and structural 47 
preferences are selected for during their evolution and amplification. 48 
 49 
 50 
 51 
 52 
Introduction  53 
 54 
All viruses are prone to replication errors that can lead to the generation of 55 
defective viral genomes (DVGs) . DVGs have lost at least one essential gene 56 
required for replication and, therefore, only replicate in the presence of a standard, 57 
non-defective (ND) virus that provides the missing functions. DVGs may also act as 58 
“interfering” genomes (defective interfering particles; DIs) that attenuate the 59 
replication of the co-infecting standard virus. Advances in molecular techniques have 60 
contributed in revealing the role of DVGs in triggering antiviral immunity and it is 61 
rapidly becoming more apparent that DVGs can impact the outcome of natural 62 
infections, while driving virus‐host co‐evolution, and perhaps promoting virus 63 
persistence [for reviews on DIs and DVGs see (1-7)]. Attention has also been drawn 64 
towards the use of DVGs as antivirals and vaccine adjuvants due to their potent 65 
interfering and immunostimulatory properties (8, 9). However, the molecular 66 
mechanisms that regulate the generation and amplification of DVGs remain largely 67 
unknown.  68 
Parainfluenza virus type 5 (PIV5) has a non-segmented negative-sense RNA 69 
genome of 15,246 nucleotides (nts), which encodes eight transcription units (3’-N-70 
V/P-M-F-SH-HN-L-5’), and also carries non-coding leader (Le) and trailer (Tr) 71 
sequences at its 3’ and 5’ ends, respectively [for a review on the molecular biology of 72 
PIV5 see (10) and paramyxoviruses in general (11)]. The genome and antigenome 73 
are encapsidated by nucleoprotein (NP) forming viral ribonucleoprotein complexes 74 
(RNPs) that protects the viral RNA from degradation, prevents its recognition by the 75 
host antiviral responses and provides the template required for transcription and 76 
replication of viral RNA. The virally encoded RNA-dependent RNA polymerase 77 
(RdRp) complex recognizes the genomic (Le) promoter elements and drives the 78 
expression of viral mRNAs through recognition of cis-acting gene start (Gs) and 79 
gene end (Ge) elements that encompass each gene. The RdRp also initiates 80 
replication of a full-length antigenome from Le. The mechanisms that enable the 81 
RdRp to ignore the cis-acting elements of the transcription units are not fully 82 
understood but are dependent upon the concentration of NP being sufficient to 83 
promote the concurrent encapsidation of replicating genomes and antigenomes (12). 84 
The encapsidated antigenome acts as the template for genome replication, which is 85 
initiated at the antigenomic (Tr) promoter. Le and Tr elements must be in the correct 86 
hexamer phase in relation to the enapsidated genomes and antigenomes for RdRp 87 
to recognise the encapsidated RNA and initiate virus transcription and replication 88 
(13, 14). Initiation of RNA synthesis at the Le and Tr promoters are thought to be 89 
mechanistically similar, although the Tr replication promoter is stronger than the Le 90 
replication promoter, thereby ensuring more genomes are produced than 91 
antigenomes. Efficient viral replication also requires the virus genomes to follow the 92 
‘rule of six’, meaning that the virus genome must be a multiple of six presumably 93 
because during the formation of the RNPs, 6 nts are associated with one 94 
encapsidating NP (15).  95 
 96 
Two major types of DVGs have been described for paramyxoviruses; DVGs 97 
that contain internal deletions but retain their 3’ Le and 5’ Tr sequences (16, 17), and 98 
trailer copyback DVGs, which maintain an authentic 5’ end terminus and a segment 99 
of the viral genome flanked by a reverse complementary version of this segment. In 100 
cells in which both ND geneomes and DVGs are replicating,  both internal DVGs and 101 
copyback DVGs will have a replicative advantage over ND genomes because of their 102 
smaller genome size. Furthermore, because trailer copyback DVGs have a strong 103 
(Tr) replication promoter at one end and its complement at the other, it is likely that 104 
trailer copyback DVGs will have a replicative advantage over DVGs with internal 105 
deletion (18-21). Although, the precise method for the generation of copyback DVGs 106 
is not fully understood, the widely accepted mechanism is that copyback DVGs are 107 
produced when the viral polymerase detaches from the template and reattaches to 108 
the nascent strand, which is then copied back. It has been long thought that the 109 
generation of copyback DVGs was a random event generated by the low-fidelity viral 110 
polymerases (21). However, the process of DVGs generation may not be as 111 
stochastic as initially proposed; previous studies have shown that specific sequences 112 
in the genome of vesicular stomatitis virus (VSV)  favour the generation of defective 113 
RNAs (22). Additionally, a recent study has shown that the generation of DVGs in 114 
respiratory syncytial virus (RSV) infections may favour specific regions of the 115 
genome suggesting the existence of hotspots that act as rejoin points for the viral 116 
polymerase during the formation of copyback DVGs (23).   117 
 118 
Paramyxoviruses are poor activators of early innate immunity for two main 119 
reasons. Firstly, they encode IFN antagonists that can both inhibit the activation of 120 
the IFN-induction cascade and can block IFN signalling (reviewed in (24-27)). In the 121 
case of PIV5, its IFN antagonist, the V protein, interacts with, and blocks the activity 122 
of, MDA5 (melanoma differentiation-associated protein 5)  (28, 29) as well as binding 123 
to LGP2 (laboratory of genetics and physiology 2) to negatively regulate RIG-I 124 
(retinoic acid-inducible gene I) (30). In addition, PIV5-V targets STAT1 for 125 
proteasome-mediated degradation to block IFN-signalling (31). Paramyxoviruses 126 
also tightly control virus transcription and replication, thereby limiting the production 127 
of pathogen-associated molecular patterns (PAMPs) that active pathogen 128 
recognition receptors (PRRs) and the IFN response (32, 33). However, during 129 
replication paramyxoviruses make mistakes, including the generation of copyback 130 
DVGs. Copyback DVGs are powerful inducers of innate immune responses both in 131 
vitro and in vivo (18, 19, 34-39). DVG engagement of PRRs activate a number of 132 
cellular kinases and transcription factors (e.g. IRF3, NF-kB) that regulate the 133 
expression of several cytokines, including interferons (IFNs), tumour necrosis factor 134 
(TNF) and interleukin 6 (IL-6) (reviewed in (40, 41), and can stimulate DC maturation 135 
and enhances antigen‐specific immunity to pathogen‐associated antigens (38, 42). 136 
 137 
The molecular mechanisms that dictate the generation and accumulation of 138 
DVGs remain unknown. Current evidence suggests that both host and viral factors 139 
can influence the generation of DVGs. Indeed, host species and cell type used for 140 
virus propagation affects the amplification of DVGs produced by certain viruses such 141 
as influenza viruses and West Nile virus (43, 44). It has also been previously noted 142 
that PIV5 (SV5) DVGs could readily be generated in Vero cells, they could not be 143 
generated in MDCK cells (45), although the reason for this was not investigated. 144 
Viral factors such as low-fidelity viral polymerases can lead to the over production of 145 
DVGs due to increased recombination rates (46), whilst the loss of viral accessory 146 
proteins, such as the C protein of Sendai virus, can also promote the accumulation 147 
of DVGs (47, 48).   148 
 149 
In this study, we show that the generation of copyback DVGs readily occurs 150 
during PIV5 replication, but that their subsequent amplification is restricted by their 151 
induction of innate intracellular responses. In addition, we used high throughput 152 
sequencing (HTS) to characterise PIV5 copyback DVGs and suggest that whilst 153 
there are no sequence specific breaks or rejoin points for their generation, size and 154 
structural constraints influence their subsequent amplification and evolution. 155 
 156 
 157 
Results  158 
 159 
Induction of IFN by PIV5 160 
 161 
We have previously shown that during the development of PIV5 (and other negative 162 
sense RNA viruses) plaques, only a minority of infected cells are responsible for the 163 
production of IFN that induces an antiviral state in the surrounding uninfected cells 164 
(Chen et al (34) and Figure 1a). Furthermore, we, and others, have shown that 165 
paramyxovirus DVGs are primary inducers of IFN (18, 19, 34-39). We have 166 
suggested that during replication of non-defective (ND) paramyxoviruses (that must 167 
initiate virus replication during plaque development), DVGs are produced which 168 
subsequently activate the IFN induction cascade in a minority of cells as the virus 169 
spreads during plaque development (34). To quantify this, A549:pr(IFNβ)GFP 170 
reporter cells (for characterisation of this cell line see (18, 34, 35) were infected with 171 
PIV5-W3 at an MOI of 0.001 and at 2 days p.i. the cells were trypsinized, fixed, 172 
stained for NP and the number of GFP-positive (GFP+ve) cells was compared to the 173 
number of cells positive for NP by FACS analysis (Figure 1b). At this time p.i. the 174 
ratio of infected cells in which the IFN- promoter had not been activated (NP 175 
positive; GFP negative cells) to cells in which the IFN- promoter had been activated 176 
(GFP positive cells) was approximately 30:1. 177 
 178 
We next determined whether DVGs were enriched in cells which the IFN-induction 179 
cascade had been activated following a low multiplicity spreading infection.  180 
A549:pr(IFNβ)GFP cells were infected at an MOI of 0.0001 pfu/cell, with a DVG-poor 181 
preparation of PIV5 (to ensure that the likelihood of input DVGs being replicated and 182 
amplified was minimal) and at 4 days p.i. the cells were trypsinized and the GFP+ve 183 
cells separated from the GFP-negative (GFP-ve) cells by FACS (Figure1, panel c). 184 
Quantitative PCR was used to estimate the relative abundance of viral genomes and 185 
copyback DVGs in the separated populations. DVG primers were designed to be 186 
able to detect DVGs that we had previously identified as being produced during 187 
passage of PIV5 at high MOI (18). Viral genomes were detected using NP specific 188 
primers in which the primer used for the reverse transcription (RT) step hybridized to 189 
genomic RNA. The results showed that there was approximately a five-fold greater 190 
abundance of DVGs in the GFP+ve compared to the GFP-ve cells (Figure 1d). In 191 
contrast, there was approximately a four-fold greater abundance of genomic RNA in 192 
the GFP-ve cells compared to the GFP+ve cells.  193 
 194 
These observations strongly support the conclusion that during the replication of 195 
PIV5, DVGs are rapidly produced and that these are primarily responsible for the 196 
induction of IFN. This conclusion is further supported by the observation that a DVG-197 
rich preparation of wt PIV5 (vM8) can be “cured” of DVGs by passage at a low MOI 198 
and that the resulting DVG-poor preparation is a poor inducer of IFN (Figure 1e). 199 
(Note: as described in Killip et al,(18) vM designates how many passages a virus has 200 
been passaged at high moi, sequential preparataions are referred to as vM1, vM2 201 
etc). Nevertheless, the observation that low levels of DVGs can be detected in GFP-202 
ve cells and genomic RNA can be detected in GFP+ve cells suggests that either 203 
within individual cells there may be a dynamic balance between the activation of the 204 
IFN-induction cascade by DVGs and the ability of ND virus to block its activation, or 205 
that in some infected cells the IFN-induction cascade can be activated by PAMPs 206 
produced during ND virus replication.   207 
 208 
To further investigate the interaction of ND virus with DVGs and the activation of the 209 
IFN response, A549:pr(IFNβ)GFP cells were infected with different dilutions of, i) a 210 
DVG-poor preparation PIV5 wt (Figure 2, panels A to D), ii) a DVG-rich preparation 211 
of PIV5-VΔC (vM2; Figure 2, lanes E to H), or iii) were co-infected with PIV5 (wt) and 212 
different dilutions of the DVG-rich preparation of PIV5-VΔC (vM2; Figure 2, lanes I to 213 
L). At 18h p.i. the cells were fixed, immunostained for expression of NP and the 214 
expression of NP (Y-axis) was plotted against GFP expression (X-axis). >90% of the 215 
cells infected with the 10-1 dilution of PIV5 wt were strongly positive for the 216 
expression of NP (Figure 2A), of which approximately 1.5% were also GFP +ve. In 217 
contrast, although 89% of cells were GFP+ve in cells infected with the 10-1 dilution of 218 
PIV5-VΔC (vM2), a minority of these cells were strongly positive for NP (Figure 2E).  219 
In co-infection experiments, and in agreement with the results of Killip et al. (2013), 220 
high levels of DVGs did inhibit the expression of NP by PIV5 (wt) in a concentration-221 
dependent manner (Figure 2I – 2L). However, although there was some reduction in 222 
the number of GFP +ve cells upon co-infection of the 10-1 dilution of PIV5-VΔC 223 
(vM2) with the 10-1 dilution (eqivalent to ~ 1 pfu/cell)  of PIV5 (wt; compare lanes E 224 
and I), PIV5  (wt) did not inhibit the induction of GFP by PIV5-VΔC (vM2) in the 225 
majority of cells. 226 
 227 
Next to determine whether at higher ratios of ND virus to DVGs the ND virus could 228 
block the activation of the IFN-induction cascade by DVGs, A549:pr(IFNβ)GFP 229 
reporter cells were co-infected with decreasing amounts of wt PIV5-W3 (starting at 230 
200 pfu/cell) and a 10-2 dilution of PIV5-VΔC (vM2) that still activated the IFN-231 
induction cascade in the majority of the cells. This experiment clearly showed that at 232 
high ratios of ND viruses to DVGs the ND virus can block DVG activation of the IFN-233 
induction cascade (Figure 3). Taken together with the experiment presented in 234 
Figure 2, these results suggest that within cells infected with both ND virus and 235 
DVGs there will be a balance between the ability of the DVG to induce IFN response 236 
and the ND virus to block the response.  237 
 238 
Innate intracellular antiviral responses limit the amplification of DVGs. 239 
 240 
Although from the experiments described above it was clear that copyback DVGs 241 
are generated during replication of PIV5 in A549 cells, we noted that, in preliminary 242 
experiments,we could not produce and maintain DVG-rich virus stocks in these cells, 243 
in contrast to Vero cells. We speculated that this may be because DVGs induce 244 
interferon and/or other innate intracellular antiviral responses that inhibit their 245 
replication in IFN-competent A549 cells. To test this, we passaged PIV5-VΔC in 246 
A549 cells that were deficient in a variety of innate responses. We used PIV5-VΔC, 247 
rather than wt PIV5, in these experiments because we had previously noted that high 248 
DVG-rich stocks of PIV5-VΔC could be generated in as little as 2 passages 249 
(generating vM2 of PIV5-VΔC; Killip et al)) of our working stock of PIV5-VΔC at high 250 
MOI in Vero cells. DVG-rich stocks of PIV5-VΔC (vM2) are a mixture of DVG- and 251 
ND-viruses, with DVGs to ND genomes ratios of up to 60:1 (18).  252 
 253 
The cell lines used in these experiments were naïve A549 cells, A549/V, A549/Npro, 254 
A549/V/Npro and A549/shIFIT1. A549/V cells cannot respond to IFN as they 255 
constitutively express the V protein of PIV5 which targets STAT1 for proteasome-256 
mediated degradation (31); A549/Npro cells cannot produce IFN as they constitutively 257 
express Npro from bovine diarrhoea virus, which targets IRF-3 for degradation (49); 258 
A549/shIFIT1 stably express shRNA against IFIT1 (which is the primary ISG that 259 
inhibits PIV5 replication) blocking its expression (50); A549/Npro/V cells cannot 260 
produce or respond to IFN. In the characterisation of these cell lines, as predicted, 261 
since IFIT1 expression is upregulated both by IFN and by activated IRF-3, IFIT1 was 262 
not upregulated by IFN- in A549/V cells but was upregulated by the DVG-rich stock 263 
of PIV5-VΔC vM2, presumably through the activation of IRF-3. In contrast, IFIT1 was 264 
upregulated by IFN-α in A549/Npro cells but was not upregulated by infection of these 265 
cells by PIV5-VΔC vM2.  IFIT1 was not upregulated by either IFN-α or PIV5-VΔC 266 
vM2 in A549/Npro/V cells or in A549/shIFIT1 cells (Figure 4).  267 
 268 
These cell lines were sequentially infected six times with PIV5-VΔC at a high MOI  269 
(vM1 to vM6) as previously described (18) and samples of the supernatants at each 270 
passage were used to infect to A549:pr(IFNβ)GFP reporter cells at different dilutions. 271 
At 18h p.i. infected cells were trypsinized and the percentage of GFP+ve cells (from 272 
a sample size of 10,000) was determined by flow cytometry (Figure 5). Although no 273 
significant difference could be seen in the number of GFP+ve cells in cells infected 274 
with virus isolated from any of the cell lines after the first passage (vM1), by vM3 the 275 
percentage of GFP+ve cells in virus harvested from A549:Npro and A549/Npro/V cell 276 
lines was significantly higher than from virus harvested from any of the other cell 277 
lines. Indeed, by vM4 >60% of the reporter cells were GFP+ve following infection 278 
with a 10-1 dilution of virus harvested from both the A549/Npro and A549/Npro/V 279 
expressing cell lines, whilst only approximately 15-20% of cells were GFP+ve using 280 
virus passaged in naïve A549 cells, A549/V cells and A549/shIFIT1 cells (Figure 5b). 281 
By vM6 there was an approximate log10 reduction in viral titres in the supernatant 282 
derived from PIV5-VΔC-infected A549-Npro and A549/Npro/V cells (Figure 5), 283 
presumably due to the high levels of DVGs present in these virus preparation (as 284 
shown below).  285 
 286 
Molecular characterisation of the DVGs 287 
To determine whether the efficiency of activation of the IFN- promoter correlated 288 
with the presence of DVGs, nucleocapsids were purified from cells infected with the 289 
vM5 and vM6 virus stocks described above and subjected to high throughput 290 
sequencing as described previously (51). ViReMa software (52) was used to detect 291 
and characterise DVGs. Consistent with previous reports (18), reads generated by 292 
DVG-rich stocks of virus produce an obvious increase in read coverage at the 5’ end 293 
of the genome (e.g., A549/Npro vM5 reads, Figure 6a). To estimate of the ratio of 294 
DVGs to ND virus genomes the average number of reads per nucleotides (nt) from a 295 
region of the genome that was common to all the DVGs (14874-15174: X) minus the 296 
average number of reads per nt prior to the first identified breakpoint (1–14000: Y) 297 
was divided by the average number of reads per nt prior the first identified breakpoint 298 
(1–14000: Y), i.e. X-Y/Y (Table 1). In addition, the percentage of DVG sequence 299 
reads to total cell RNA reads was estimated (Table 1 and Figure 6b). These data 300 
clearly showed that there were significantly higher amounts of DVGs in virus stocks 301 
made from virus passaged in A549/Npro and A549/Npro/V cells than in any of the 302 
other cell lines.  303 
 304 
Three major DVGs, first identified by Killip et al (18) as the most abundant DVGs in a 305 
vM2 preparation of PIV5-VΔC prepared in Vero cells, were identified as the most 306 
abundant contributors to the total DVG population in all the cell lines tested here 307 
(regardless of the relative abundance of DVGs present), except for virus isolated 308 
from vM6 infected A549/shIFIT1 cells in which a fourth DVG had become a major 309 
contributor to the overall DVG population (Table 1) (Note: the starting vM0 stock 310 
used in this study was closely related to that used in the study of Killip et al (18)). 311 
Five additional minor DVGs were also identified, these were almost exclusively found 312 
in both Npro expressing cell lines and contributed <1% to the total DVG population. 313 
Sequence analysis of the breakpoints (points at which RdRp leaves the antigenome) 314 
and reattachment points (where the RdRp attaches to the nascent strand of RNA 315 
and continues to process) for each DVG showed no obvious sequence similarities at 316 
the copyback junction where the RdRp leaves the antigenome template. However, 317 
there did appear to be a 25 nt region of the nascent strand (genome positions 15,133 318 
to 15,157 nt) where the RdRp may preferentially reattach. 319 
 320 
To determine whether this 25 nt reattachment region was the same, in an 321 
independent experiment in which DVGs were generated, we refined and expanded 322 
our analysis of the sequence data on DVGs generated by high MOI passage of wt 323 
PIV5 in Vero cells previously published by Killip et al. (18). Not only was sequence 324 
data available for the vM12 passaged wt PIV5, but data was also available for vM8 325 
virus, which was not analysed in Killip et al (18). Whilst there were two regions, 326 
14812 to 14870 and 15062 to 15153, of the nascent strand, which were identified as 327 
reattachment points for the majority of DVGs in this passage series, neither of these 328 
were the same as the 25 nt reattachment region identified in the PIV5-VΔC passage 329 
series.  330 
 331 
Discussion 332 
 333 
Following a low multiplicity infection of cells with DVG-poor preparations of viruses 334 
the chances of an individual cell being infected with both a ND replicating virus and a 335 
DVG that was present in the original virus stock is extremely low. However, we show 336 
here that by 2 days post infection of A549 cells with DVG-poor preparations of wt 337 
PIV5 at an MOI of 0.001 sufficient numbers of DVGs had been produced to activate 338 
the IFN-induction cascade in 0.78% of cells (Figure 1), demonstrating that the 339 
generation of DVGs is a very common event during PIV5 replication. We also show 340 
that high levels of ND virus can block the DVG-mediated activation of the IFN 341 
induction cascade, presumably through the IFN antagonism of the V protein or 342 
because at high levels of NP the DVG PAMP becomes encapsidated. This data, 343 
together with the observation which shows DVGs can be detected in cells in which 344 
the IFN-induction cascade has not been activated, suggests a scenario in which 345 
DVGs are generated during virus replication in cells in which the virus has blocked 346 
the activation of the IFN-induction cascade. However, as copyback DVGs are 347 
packaged into virus particles, “infectious” DVGs released from these cells may 348 
activate IRF3 and the IFN-induction cascade in some surrounding uninfected cells 349 
before the ND wildtype virus can block this from occurring, thereby explaining why a 350 
significant number of GFP+ve cells are negative for NP staining.  However, in the 351 
experiment in which we infected cells with PIV5 (wt) at a low MOI and measure the 352 
percentage of cells positive for NP and GFP  (Figure 1b), approximately 60% of 353 
GFP+ve cells (0.78% of the 1.26% of cells that were GFP +ve) were also positive for 354 
NP. For technical reasons we could not separate the NP+ve/GFP+ve cells from the 355 
NP-ve/GFP+ve cells and probe for the presence or absence of DVGs. It is possible 356 
that in these NP+ve/GFP+ve cells DVGs had activated IRF3 but that the subsequent 357 
induction of an antiviral state did not occur fast enough for IFIT1 to block virus 358 
protein synthesis, whilst virus replication did not occur quickly enough to block DVG-359 
mediated activation of IRF-3. Alternatively, the IFN-induction cascade may have 360 
been activated in a proportion of infected cells by PAMPs produced by virus 361 
replication in the absence of DVGs. This latter hypothesis appears to be supported 362 
by the observation that during passage of PIV5-VΔC in A549, A549/V and 363 
A549/shIFIT1 cells there was an increase in the number of GFP+ve cells between 364 
vM1 and vM6 (Figure 5) without an obvious increase in the number of DVGs. We are 365 
currently trying to distinguish between these two possibilities.  366 
 367 
DVG induction of innate intracellular responses limits their replication and 368 
accumulation following high MOI passage. Thus, DVGs accumulated to much higher 369 
levels in A549:BVDV/Npro cells than in naïve A549 cells. However, surprisingly, 370 
DVGs did not accumulate in A549:PIV5/V cells or A549/shIFIT1 cells. Furthermore, 371 
DVGs did not accumulate to higher levels in A549 cells that constitutively express 372 
both BVDV/Npro and PIV5/V proteins than in cells that only express BVDV/Npro. 373 
These results show that the restriction factor(s) that limits DVG amplification can be 374 
induced by DVGs independently of IFN signalling and may be dependent upon IRF-3 375 
activation.  However, this factor is not IFIT1, which can be induced by IRF-3 and is 376 
the primary ISG that inhibits PIV5 protein synthesis (50, 53). These results are 377 
therefore in agreement with those of Tapia et al., which showed that Sendai virus 378 
copyback DVGs are generated in the lung of mice independently of type I IFN 379 
signalling (37).  380 
 381 
HTS was used to determine and characterise the DVGs produced by high MOI 382 
passage of PIV5-VΔC in the different cell-lines and to determine their relative 383 
abundance. No DVGs with different structures to copyback DVGs, including internal 384 
deletions, were selected in any of the different cell-lines. Furthermore, the most 385 
abundant DVGs were similar in all the virus preparations, regardless of the cell line 386 
used for the passage series and were detected in the original vM0 stock of PIV5-387 
VΔC.  Thus, it is highly likely that the different DVGs had already been generated by 388 
passage of PIV5-VΔC prior to the beginning of this passage series, and that they 389 
were or were not amplified during passage, depending on whether or not the cells 390 
express BVDV/Npro.  391 
 392 
It has been suggested for RSV that there are AU-rich hotspot regions that are the 393 
rejoin points for RSV copyback DVGs (23). Similarly, for PIV5-VΔC there is a 25nt-394 
long AU-rich region that may serve as a rejoin point. However, the DVGs generated 395 
in an independent passage of PIV5 (wt) did not share this rejoin point. Furthermore, 396 
the 4 main rejoin points for PIV5 (wt) DVGs were not particularly AU-rich, having the 397 
same content ratio as the rest of the genome. Hexamer phasing is essential for 398 
promoter recognition of the RdRp and initiation of virus transcription and replication 399 
and may play a role in RNA editing and influence RdRp disengagement at gene 400 
junctions. It may therefore have also influenced where the RdRp disengages from 401 
the template antigenome to generate DVGs. However, on analysis, the hexamer 402 
phase of the PIV5 (wt) and PIV5-VΔC copyback junctions varied between the DVGs, 403 
suggesting that hexamer phasing does not play a role in DVG generation.  404 
 405 
From our analysis, there is some suggestion that initially a relatively large copyback 406 
DVG may be generated during replication, but on further passage this may further 407 
evolve to generate smaller, more efficiently replicated DVGs, that eventually would 408 
outcompete the original. Thus, for PIV5 (wt) there are fewer DVGs at vM12 than vM8 409 
and the major DVG (14496-15062) has increased from 87% to 96% (Table 2). 410 
Similarly, in the PIV5-VΔC passage series there is a significant reduction in the 411 
relative abundance of the largest DVG (14043/4-15023/4) between vM5 and vM6 412 
virus in all the cell-lines. Also, although it is clear from this study and that of Murphy 413 
et al. (13), copyback DVGs do not necessarily need to obey the rule of six, the 414 
contribution of those that do not decrease during passages of both PIV5 (wt) and 415 
PIV5-VΔC. However, there does appear to be a minimum length for the Tr promoter 416 
as no DVG has been identified with <89 nucleotides of the 5’end (Tables 1 and 2). 417 
The requirement for this probably reflects the need to conserve the hexamer phase 418 
of the CRII element within the promoter. Since the Tr promoter is found in opposite 419 
orientations at both ends, the observation that the minimum size of any DVG 420 
identified was 389 nucleotides (which includes 180 nucleotides of both Tr promoters) 421 
suggests that there may be a minimum optimal size for DVGs and thus for the loop 422 
structure. Furthermore, the optimal size for a DVG may be greater than 389 423 
nucleotides as this small DVG was only a minor population in vM8 preparations of 424 
DVG-rich PIV5 (wt) preparations and had been lost by vM12; the major DVG in both 425 
vM8 and vM12 preparations being 936 nucleotides long (Table 2). The major DVG in 426 
DVG-rich preparations of PIV5-VΔC was 468 nucleotides long (Table 1). Thus, whilst 427 
there appears to be no sequence-specific break or rejoining points for the generation 428 
of PIV5 copyback DVGs, there appears to be region, size and structural preferences 429 
selected for during for their amplification. However, more detailed studies are 430 
needed to fully understand the generation and molecular evolution of DVGs.  431 
 432 
All viruses produce DVGs during their replication, and these may impact on disease 433 
outcomes by interfering with the replication of ND virus and by inducing innate 434 
immune responses. Whilst the induction of innate antiviral responses may be of 435 
major benefit to the host in limiting virus replication, overproduction of DVGs may 436 
also over stimulate the immune response leading to a cytokine storm and increased 437 
disease severity. It is therefore of interest that, at least for PIV5, the induction of 438 
early intracellular innate responses (that are not induced in cells infected with ND 439 
virus) selectively reduces the amplification of DVGs compared to ND virus.  Also, the 440 
observation that early innate intracellular responses limit the amplification of DVGs 441 
suggests that if DVG-rich virus preparations are manufacture for therapeutic 442 
purposes, e.g. as vaccine adjuvants, it will be important to use cell lines in which 443 
such responses are blocked. 444 
 445 
Materials and Methods 446 
 447 
Cells and virus infection 448 
 449 
Vero and A549 cells (obtained from the European Collection of Authenticated Cell 450 
Cultures; ECACC) and A549 derivatives A549/Npro (49), A549/V (18), A549:V/Npro, 451 
A549:shIFIT1 (50) and A549/pr(IFN-).GFP (34) were grown as monolayers at 37°C 452 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 453 
bovine serum. PIV5 wt (strain W3A) and PIV5-VΔC were grown and titrated under 454 
appropriate conditions in Vero cells. Virus infections were carried out in DMEM 455 
supplemented with 2% fetal bovine serum.  456 
 457 
Immunofluorescence, immunoblot analysis and FACS: The procedures for 458 
immunoblotting and immunofluorescence have previously been described (54). 459 
Antibodies used in these procedures included monoclonal antibodies (mAbs) to the 460 
phosphoprotein and nucleoproteins of PIV5 (PIV5-Pk, PIV5-NPa, (55)) and rabbit 461 
polyclonal antibodies to IFIT1 (Santa Cruz Biotechnology: sc-82946) STAT1 (Santa 462 
Cruz Biotechnology: sc-417) and actin (Sigma: A2066). Following immunostaining, 463 
monolayers were washed with PBS, mounted using Citifluor AF-1 mounting solution 464 
(Citifluor Ltd., UK) and examined with a Nikon Microphot-FXA immunofluorescence 465 
microscope. For FACS analysis, cells were trypsinised to a single cell suspension, 466 
fixed and permeabilised as for immunofluorescence, and immunostained with the 467 
mAbs to the NP of PIV5. The cells were then incubated with a secondary antibody 468 
conjugated to phycoerythrin (PE, Abcam). The percentage of fluorescent cells, and 469 
intensity of their fluorescence in 10,000 events was determined by using the LYSYS 470 
programme on a Becton Dickinson FACScan. Analysis of flow cytometry data was 471 
performed using FlowJo software. For live cell sorting 10,000 A549:pr(IFNβ)GFP 472 
reporter cells infected with PIV5-W3 were trypsinised and resuspended in DMEM. 473 
GFP intensity was measured against side scatter (SSC). Cells were gated and 474 
sorted using the Beckman Coultere MOFLO (cytomation) into GFP +ve and GFP -ve 475 
cells and collected in individual vials.  476 
 477 
Real-Time quantitative PCR 478 
 479 
RNA was extracted from GFP +ve and GFP -ve cells using TRIzol (Invitrogen) as per 480 
manufacturer’s instructions. cDNA was generated from the extracted RNA using M-481 
MLV reverse transcriptase and virus sequences PCR amplified using GoTaq 482 
polymerase (Promega). PCR primers were designed against the virus genome and a 483 
previously identified large DVGs that had been generated during infection of A549 484 
cells from the same PIV5-VΔC virus stock (18). Oligo-dT primers were also used to 485 
generate cDNA to allow normalization of samples to housekeeping gene PPIA. The 486 
cDNA was subject to real-time qPCR reaction performed using SYBR Green-based 487 
master mix (MESA Blue MasterMix Plus SYBR Assay; Low ROX, Eurogentec). 488 
Primer concentrations were optimised for each primer pair. After activation of the 489 
polymerase for 5 mins at 95C, the cDNA underwent denaturation for 15 secs at 490 
95C and annealing/extension for 1 min at 60C for 40 cycles. Real-time qPCR was 491 
analysed by Stratagene Mx3005p thermocycler. Cycle threshold (Ct) values of the 492 
uninfected mock cells and the GFP +ve and GFP -ve infected cells were normalized 493 
to housekeeping gene PPIA to ascertain the ΔCt values. The ΔCt values of the GFP 494 
+ve and GFP -ve infected cells were then compared to those of the uninfected mock 495 
cells to determine the ΔΔCt fold difference.  496 
 497 
Generation of DVG-rich PIV5-VΔC stocks and HTS sequencing of DVGs.  498 
A549 naïve, A549/V, A549/Npro, A549:V/Npro and A549/shIFIT1 cell lines were 499 
infected with PIV5-VΔC (vM0) cells grown in 75-cm2 flasks were infected at a 500 
multiplicity of infection (MOI) of 5 PFU/cell. The culture medium was harvested every 501 
2 to 3 days: half was frozen at -70°C for subsequent analysis, while the other half 502 
was used to infect another 75-cm2 flask. Sequential preparations of these stocks are 503 
referred to as vM1, vM2, etc. RNA was extracted from purified viral RNPs as 504 
previously described (18) and sequenced in the Glasgow Polyomics Facility, 505 
University of Glasgow, using an Illumina GA2x platform. Reads were aligned to 506 
PIV5-VΔC reference sequence using BWA (56) and visualized using Tablet (57). 507 
DVGs were characterised using ViReMa software. The breakpoint junctions of each 508 
population of copyback DVG were determined and the number of reads containing 509 
the breakpoint were quantified. The contribution of individual DVGs to the total DVG 510 
population was determined. The abundance of the total DVG population was 511 
compared to the total cell RNA reads. To determine the ratio of DVGs to ND virus 512 
genomes the SAM files generated from the alignment were processed using 513 
SAM2CONSENSUS software (https://github.com/vbsreenu/Sam2Consensus) to 514 
determine the average coverage of reads at each nucleotide. The average coverage 515 
of ND virus genomes (approximately 1-14000 nts that excludes any contribution from 516 
reads generated from DVGs) and the average coverage of the reads from a region of 517 
genome common to all DVGs (14874 to 15246 nts minus the average coverage from 518 
nucleotide 1 -14000) were compared.  519 
  520 
 521 
 522 
Table 1. Characterisation of the genome structure and relative abundance of 523 
copyback DVGs in PIV5-VΔC infected cell lines. Nucleocapsids were purified from cells 524 
used to generate the vM5 and vM6 passage series of PIV5-VΔC generated in derivatives 525 
of A549 cells and subjected to sequencing. ViReMa software was used to identify 526 
breakpoint and rejoin junctions of DVGs. The sequence shown in black indicates the 527 
upstream 10nts antigenome sequence and in red the 10 nt downstream genome sequence 528 
of the junctions. Underlined nts indicates a copyback junction where the exact genome 529 
position of the copyback junction could not be determined and therefore could be at any of 530 
the underlined nts. Also shown are the number of reads generated from DVGs compared 531 
to the total cell RNA reads. SAM2CONSENSUS software was used to estimate of the ratio 532 
of DVGs to ND virus genomes. The average number of reads per nucleotides (nt) from a 533 
region of the genome that was common to all the DVGs (14874-15174,: X) minus the 534 
average number of reads per nt prior to the first identified breakpoint (1–14000: Y) was 535 
divided by the average number of reads per nt prior the first identified breakpoint (1–536 
14000: Y), i.e. X-Y/Y (Table 1). The length of the DVGs and whether they conformed to the 537 
rule of six is also shown.  538 
 539 
  540 
Table 2. Characterisation of the genome structure and relative abundance of 541 
copyback DVGs generated in PIV5 (W3) infected Vero cells. The passage series 542 
that was used to generate the vM8 and vM12 RNA used in this analysis has been 543 
previously described (18) and the HTS data generated was subjected to the same 544 
analysis as described in Table 1. The greyed italicised sequence present in the 545 
14962 DVG is an insertion of 9nts between the identified detachment/reattachment 546 
positions. 547 
  548 
  549 
 550 
 551 
Figure Legends  552 
Figure 1: DVGs are enriched in GFP+ve A549:pr(IFNβ)GFP cells infected with wt 553 
PIV5. a) A549:pr(IFNβ)GFP reporter cells in which GFP expression is under the IFNβ 554 
promoter were grown on coverslips and infected with PIV5-W3 at an MOI of 0.001 pfu/cell. 555 
At 2 days p.i. cells were fixed, permeabilized and stained with an anti-NP monoclonal 556 
antibody (red). The nuclei were also visualized by staining the cells with DAPI (blue). b)  557 
A549:pr(IFNβ)GFP reporter cells were mock infected or infected with PIV5-W3 at an MOI 558 
of 0.001 pfu/cell for 2 days. Cells were trypsinised, fixed and stained for NP. The 559 
percentage of GFP +ve and NP +ve cells in a total cell population of 10,000 cells was 560 
determined by flow cytometry using the Beckman Coulter MOFLO (Cytomation) cell sorter 561 
(gating lines shown in pink). c)  Flow cytometry of A549:pr(IFNβ)GFP reporter cells that 562 
were mock infected or infected with PIV5-W3 at an MOI of 0.0001 pfu/cell for 4 days. Cells 563 
were trypsinised and resuspended in 2%FCS/PBS. A population of 10,000 cells was 564 
immediately sorted into GFP +ve and GFP -ve cells (gating shown in pink boxes) by flow 565 
cytometry using the Beckman Coulter MOFLO (Cytomation) cell sorter. Collected cells 566 
were immediately pelleted by centrifugation and the RNA TRIzol extracted prior to RT-567 
QPCR. GFP was plotted against cells forward side scatter (FSS). d) The RNA extracted 568 
from GFP-ve and GFP+ve sorted cells (panel c) was subjected to RT-qPCR to determine 569 
the relative abundance of genomic RNA to copyback DVG; the ΔCt values normalized to 570 
housekeeping gene PPIA. The ΔCt values were then compared to mock infected 571 
A549:pr(IFNβ)GFP reporter cells to ascertain the ΔΔCt the fold difference. The relative 572 
abundance of ND virus genomes and DVGs is shown in blue and black respectively. e) 573 
Vero cells were infected with the vM8 DVG-rich preparation of PIV5 (W3) (Killip et al (18)) 574 
at low (0.001 pfu/cell) and high (10 pfu/cell) MOIs. At 48h p.i. the supernatant from these 575 
cells harvested and used to infect A549:pr(IFNβ)GFP reporter cells grown on coverslips. 576 
At 24 h p.i. the infected A549:pr(IFNβ)GFP were fixed and stained with an anti-NP 577 
monoclonal antibody (red).  578 
 579 
Figure 2 DVGs can block PIV5 replication whilst inducing the IFN-induction cascade. 580 
A549:pr(IFNβ)GFP reporter cells were infected with either wt PIV5 (panels A-D) or PIV5 581 
VΔC vM2 (panels E-H) at 10 fold dilutions starting and an MOI of 1 pfu/cell. Cells were 582 
also co-infected with PIV5 (wt) and PIV5 VΔC vM2: wt PIV5 at 10-1 dilution from stock (i.e. 583 
I pfu/cell), PIV5 VΔC vM2 at 10-fold dilutions at 10-1, 10-2, 10-3, 10-4 (I-L). At 18h p.i. the 584 
cells trypsized to a single cell suspension, fixed and PE-immunostained for NP. Samples 585 
were analysed by flow cytometry on a Becton Dickinson FACSCaliber flow cytometer 586 
machine. GFP intensity in single cells is shown on the X-axis, NP-PE on the Y-axis.  587 
 588 
 589 
Figure 3: High levels of wt PIV5 can block DVG induction of GFP in 590 
A549:pr(IFNβ)GFP reporter cells. Monolayers of A549:pr(IFNβ)GFP reporter cells 591 
in 96 well microtitre plates were co-infected with a 10-2 dilution of PIV5 VΔC vM2 (the 592 
highest dilution that still induced GFP expression in ~80% of cells) and doubling 593 
dilutions (wells 2-11 in a row of 12 wells) of a DVG-poor stock of wt PIV5 starting at a 594 
concentration of 200 pfu/cell. No PIV5 VΔC vM2 was added to well 1 and no DVG-595 
poor wt PIV5 was added to well 12. At 24h p.i. the cells were fixed and GFP 596 
expression was measured on a Tecan Infite plate reader and the fold increase, 597 
compared to uninfected cells, calculated. Data shown represents mean values (n = 3 598 
replicates; error bars = SD)  599 
 600 
 601 
Figure 4: Characterisation of A549 and derived cell-lines following IFN 602 
treatment or infection with a DVG-rich preparation of PIV5 VC (vM2). A549, 603 
A549/V, A549/NPro, A549/V/Npro and A549/shIFIT1 cells were treated with IFN- 604 
(1,000 IU/ml), infected with PIV5-VΔC vM2, or left untreated (UI). Cell lysates were 605 
prepared after 16 h and subjected to immunoblotting for IRF3, IFIT1, STAT1, the P 606 
protein of PIV5 and actin. Note: the first 9 lanes of this figure have been previously 607 
published (18) 608 
 609 
Figure 5 610 
GFP induction in A549:pr(IFNβ)GFP cells following infection with vM1 to vM6 of 611 
PIV5-VΔC grown in A549 and derived cell-lines. A549:pr(IFNβ)GFP reporter cells were 612 
mock infected or infected for 18h with 10-3 dilutions of a DVG-poor stock of wt PIV5, a vM0 613 
or vM2 stocks of PIV5VΔC prepared in Vero cells, or with a 10-1, 10-2 or 10-3 dilution of the 614 
vM1 to vM6 stocks of PIV5VΔC prepared in A549, A549/V, A549/Npro, A549/Npro/V or 615 
A549/shIFIT1.  At 18h p.i. the cells were trypsinized, fixed and stained for NP (PE stained). 616 
The relative intensity of GFP and PE staining in 10,000 cells was determined by Flow 617 
cytometry on a Becton Dickinson FACSCaliber flow cytometer machine; GFP intensity is 618 
measured on the x-axis, NP-PE on the y-axis. Panel A shows representative plotted 619 
graphs of the relative NP and GFP intensity for A549:pr(IFNβ)GFP cells infected with 10-1 620 
dilutions of DVG-poor stock of wt PIV5, vM0 and vM2 stocks of PIV5VΔC, and a 10-1 621 
dilution of the vM1, vM3 to vM6 stocks of PIV5VΔC prepared in A549, A549/V, A549/Npro, 622 
A549/Npro/V or A549/shIFIT1 cells. Virus titres in these stocks are also shown. Panel B 623 
shows the percentage of GFP+ve cells in A549:pr(IFNβ)GFP cells (as determined in panel 624 
A) infected with a 10-1, 10-2 and 10-3 dilutions of the vM1 to vM6 PIV5VΔC stocks prepared 625 
in A549, A549/V, A549/Npro, A549/Npro/V or A549/shIFIT1 cells. 626 
 627 
Figure 6: Trailer copyback DVGs in PIV5-VΔC infected cell lines. a) Nucleocapsids 628 
were purified from cells used to generate the vM6 passage series of PIV5-VΔC generated 629 
in A549/Npro cells (as also described in Table 1). The reads generated from sequencing 630 
were aligned to the PIV5-VΔC reference genome and visualised using Tablet software. 631 
The coloured vertical lines indicate the read coverage at each nucleotide. Genome 632 
positions 1-14,000 and 14874-15,174 are indicted by black arrows. b) The reads 633 
generated from DVGs were identified by ViReMa for vM5 and vM6 virus preparations as 634 
described in Table 1. The number of DVGs reads was compared to the number of total 635 
cellular reads. vM5 and vM6 are shown in blue and red respectively.  636 
 637 
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